Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Cash Flow (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Net Cash Flow data on record, last reported at $42.7 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 142.43% year-over-year to $42.7 million; the TTM value through Dec 2025 reached $112.8 million, up 3588.65%, while the annual FY2025 figure was $112.8 million, 3588.65% up from the prior year.
  • Net Cash Flow reached $42.7 million in Q4 2025 per VRDN's latest filing, down from $52.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $312.9 million in Q3 2022 and bottomed at -$188.6 million in Q4 2022.
  • Average Net Cash Flow over 5 years is $8.3 million, with a median of $513500.0 recorded in 2021.
  • Peak YoY movement for Net Cash Flow: soared 22201.19% in 2021, then tumbled 2032.6% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$96.6 million in 2021, then plummeted by 95.32% to -$188.6 million in 2022, then surged by 95.35% to -$8.8 million in 2023, then plummeted by 1048.49% to -$100.7 million in 2024, then soared by 142.43% to $42.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $42.7 million in Q4 2025, $52.3 million in Q3 2025, and $1.1 million in Q2 2025.